Market Overview

ExoCoBio Published a Research Paper on 'The World's First Exosome-Based Treatment for Atopic Dermatitis'

Share:

Achieving potential to develop fundamental treatment for atopic dermatitis

SEOUL, South Korea (PRWEB) August 24, 2018

ExoCoBio Inc., based in South Korea, published a scientific paper on that stem cell-derived exosomes dramatically relieves atopic dermatitis and inhibits a variety of inflammatory targets in the journal of Stem Cell Research and Therapy.

According to the paper, the symptoms of mice having severe atopic dermatitis were significantly improved after administration of stem cell-derived exosomes intravenously or subcutaneously, so that the level of serum immunoglobulin E (IgE), the number of eosinophils in blood, and the number of mast cells in the skin lesion were decreased. It has also been found that the number of inflammatory dendritic epidermal cells (IDECs), which are not found in normal skin but cause an allergic inflammatory response in atopic dermatitis lesions, also significantly decreased to a normal skin level after administration of stem cell-derived exosomes. In addition, the improvement of the symptoms by stem cell-derived exosomes was comparable to that of a steroid drug, Prednisolone.

While atopic dermatitis is a chronic disease depreciating the quality of life, there is no fundamental treatment to treat it yet. Currently available atopic treatments, such as anti-histamines, steroids and immunosuppressive drugs, have various side effects such as impaired immune systems, liver & kidney damage during long-term administration, etc. Inhibitory antibodies against various inflammatory cytokines such as IL-4, IL-31, TNF-alpha and IL-23 are under development or on the market to relieve atopic dermatitis symptoms. However, these treatments just relieve atopic dermatitis by blocking the function of one or two specific proteins.

Meanwhile, the new drug candidate based on stem cell-derived exosomes, which is being developed by ExoCoBio, can modulate the activity of various immune cells causing dermatitis, with a mechanism that fundamentally inhibits the production of inflammatory cytokines. Moreover, it is highly anticipated that stem cell-derived exosomes will become the first-in-class therapeutic for atopic dermatitis that has powerful anti-inflammatory activities and with little side effects for long-term repeated administration.

"It is so proud to be the world's first to publish the research results that stem cell-derived exosomes have very important therapeutic efficacy for atopic dermatitis. ExoCoBio will keep focusing on developing innovative biopharmaceuticals based on stem cell-derived exosomes," said Byong Cho, the CEO of ExoCoBio.

"Stem cell-derived exosomes are believed as a fundamental treatment for a variety of inflammatory diseases because they have strong anti-inflammatory effects. This study shows that stem cell-derived exosomes are very effective to improve severe atopic dermatitis," said Dr. Joon Lee, dermatologist and medical advisor of ExoCoBio.

Figure 1. Results showing therapeutic effects of stem cell-derived exosomes on atopic dermatitis. After administration of stem cell-derived exosomes in the mice with severe atopic dermatitis through either intravenously or subcutaneously, symptoms of atopic dermatitis were significantly improved in a dose-dependent manner.

https://stemcellres.biomedcentral.com/track/pdf/10.1186/s13287-018-0939-5

For the original version on PRWeb visit: https://www.prweb.com/releases/exocobio_published_a_research_paper_on_the_world_s_first_exosome_based_treatment_for_atopic_dermatitis/prweb15711898.htm

View Comments and Join the Discussion!